Key facts
- Notable investors include GRK Partners, Celltrion (Pharmaceuticals).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for I'MOK.
- ·The full record, as it builds
Funding rounds
No funding rounds for I'MOK. are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About I'MOK.
Provider of customized information services designed for cancer patients. The company's platform uses AI to analyze and summarize one's test results in an easy-to-understand manner, provides customized information on treatment, diet and exercise necessary for the patient's treatment stage, enabling patients to help recover from cancer.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Employees
- 4
- Website
- im-ok.co.kr/
- Ownership
- Privately Held (backing)
I'MOK. doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in I'MOK. shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on I'MOK. in its N-PORT filings yet. We sweep new filings monthly.